ZYBERNO
Stock Report
Updated Sep 1, 2026

Petros Pharmaceuticals, Inc. (PTPI)

Healthcare • OTC

$0.00

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
4.0/100
POOR BUSINESS
Petros Pharmaceuticals, Inc. (PTPI) scores 4/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-1.3%)
Debt-to-Equity (Solvency Risk):CRITICAL (14.93x)
Operating Margin (Operational Efficiency):CRITICAL (-66.5%)
Return on Capital (Capital Efficiency):CRITICAL (-4,461.2%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

Petros Pharmaceuticals, Inc. (PTPI) stock report — Zyberno Score 4/100 (POOR BUSINESS). Full financial analysis on Zyberno.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:0.00
Market Cap:$170.61K

Valuation Multiples (3)

P/B Ratio:0.24x
P/S Ratio:0.03x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:-$3.16M

Price Action & Momentum (3)

Momentum Percentile:1 / 100
% of 52-Week High:11.3%
B. Profitability Assessment

Return Metrics (5)

ROA:-0.6%
Reinvestment Rate:110.1%
Fundamental Growth Rate (g):-4,913.2%

Margin Analysis (3)

Operating Margin Ttm:-66.5%
Net Margin Ttm:-0.6%
Ebitda Margin:-11.1%

TTM Performance (3)

Gross Margin Ttm:76.3%
Operating Margin Ttm:-66.5%
Net Margin Ttm:-0.6%

Yield Metrics (2)

Earnings Yield:-$70.00K
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:65.2%
Latest Earnings Filed:2026-08-13

Revenue Growth (Linear) (1)

Revenue Growth Rate (Linear):-30.9%
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:1.25x
Quick Ratio:0.77x
Cash Ratio:1.23x

Leverage Analysis (3)

Debt To Equity Ttm:14.93x
Debt-to-Equity Ratio:14.93x
Debt To Ebitda:-999.00x

Coverage Ratios (2)

Interest Coverage Ratio:-24.05x
Times Interest Earned:-24.05

Capital Structure (4)

Working Capital:700,894.00
Cash And Cash Equivalents:3,488,595.00
Long Term Debt:$75.22K
Net Debt:-$3.34M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

Revenue TTM: $5.11M
Linear Growth: -30.9%
📊 Click to view full PTPI Revenue analysis & methodology →
Cost Of Revenue Ttm:$1.21M

Profitability Breakdown (2)

Gross profit TTM: $3.90M
Linear Growth: -27.4%
📊 Click to view full PTPI Gross Profit analysis & methodology →
-$3.40M

Bottom Line Performance (3)

-$29.07K
Income Before Tax:-$3.20M
Ebitda Ttm:-566,684.00

Operating Expenses (5)

Operating Expenses:3,397,903.00
R And D Expense:2,615,050.00
Sga Expense:3,397,903.00
Income Tax Expense:$10.50K
Interest Expense:192,413.00

Expense Ratios (3)

R And D To Revenue Percentage:360.5%
Sga To Revenue Percentage:468.4%
Ebitda Margin:-11.1%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$3.55M
Current Assets:$3.55M
Ppe Net:22,948.00
Goodwill:0.00
Intangible Assets:$3.20M

Liability Structure (4)

Total Liabilities:2,844,825.00
Current Liabilities:2,844,825.00
Long Term Debt:$75.22K
Short Term Debt:$78.17K

Equity & Capital (3)

Equity:$700.89K
Retained Earnings:-$113.24M
Common Stock:7,000,000,000.00

Working Capital Items (3)

Accounts Receivable:416,076.00
Inventory:1,349,802.00
Accounts Payable:97,282.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:120,319.00
C. Cash Flow Analysis

Operating Activities (2)

-$5.86M-$6.76M

Investment Activities (1)

Investing Cash Flow:-$4.43K

Financing Activities (3)

Financing Cash Flow:$0.00
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:9,600,000.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:2,831,219.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.89
-$1.89
Earnings Per Share Ttm:-$0.00

Revenue & Cash Per Share (2)

Sales Per Share Ttm:0.11
Operating Cash Flow Per Share:-$0.05

Book Value & Capital (2)

Book Value Per Share:$0.01
Cash Per Share:0.07

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (2)

Asset Turnover Ttm:1.06x
Working Capital Turnover Ttm:7.29x

Receivables Management (2)

Receivables Turnover Ttm:12.29x
Days Sales Outstanding Ttm:29.71

Inventory Management (2)

Inventory Turnover Ttm:0.90x
Days Inventory Outstanding Ttm:406.27

Payables & Cash Cycle (2)

Days Payable Outstanding:29.28
Cash Conversion Cycle:406.69
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:80.00
Quality Score:35.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Damodaran Growth Analysis (2)

Reinvestment Rate:110.1%
Fundamental Growth Rate (g):-4,913.2%
B. Log-Linear Regression Growth Analysis

Growth Rates (Log-Linear Regression) (1)

Revenue Growth Rate (Linear):-30.9%

Other Growth Rates (2)

Gross Profit Growth Rate (Linear):-27.4%
Book Value Growth Rate (Linear):-50.0%
C. Company Profile & Context

Corporate Information (6)

Symbol:PTPI
Company Name:Petros Pharmaceuticals, Inc.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:OTC
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:penny
Volume Category:N/A

Share Structure (3)

Shares Outstanding:47.39M
Shares Outstanding Basic:47.39M
Shares Outstanding Diluted:47.39M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-09-01 23:19:21 UTC
Data Timestamp:2026-08-22T20:02:09.496912
Scroll to Top